Shots:

• The P-II (KEYRICHED-1) trial evaluates the pCR rate of pembrolizumab in combination with trastuzumab biosimilar and pertuzumab in patients with early breast cancer with molecular HER2-enriched intrinsic subtype
• The results showed a 52% confirmed pCR rate in 46 evaluable patients, 52 (55%) had the HER2-E subtype by PAM50, 48 were included in the treatment phase, 65% had tumors & 30% were positive for lymph node involvement
• Additionally, the therapy also showed a confirmed pCR rate for HER2-positive/ HR-positive tumors & HER2-positive/HR-negative tumors (38.5% vs 58.5%) & no new safety signals were observed

Ref: Center for Biosimilars | Image: Merck